Download

Full Text

• American Diabetes Association: Diagnosis and classification of diabetes mellitus (Position Statement). Diabetes Care 29 (Suppl. 1):S43-S48, 2006
• American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity: Consensus development conference on antipsychotic drugs and obesity and diabetes (Consensus Statement). Diabetes Care 27:596-601, 2004
• De Hert M, Van Eyck D, De Nayer A: Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring. Int Clin Psychopharmacol 21 (Suppl. 2):11-15, 2006
• Peuskens H, De Hert M, Van Eyck D, Peuskens J: A case of reversible olanzapine-induced diabetes after switching to risperidone. Adv Schiz Clin Psych 1:31-33, 2004
• De Hert M, Van Eyck D, Hanssens L, Wampers M, Scheen A, Peuskens J: Rapid diabetes onset and its reversal among patients treated with second generation antipsychotics (Abstract). Eur Neuropsychopharmacol 15 (Suppl. 3):S483, 2005
• McQuade RD, Stock E, Marcus R, Jody D, Gharbia NA, Vanveggel S, Archibald D, Carson WH: A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 65 (Suppl. 18):47-56, 2004
• DeLeon A, Patel NC, Crismon ML: Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 26:649-666, 2004
• L'Italien G, Casey D, Ray S, Carson W, Marcus RN: Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo. J Clin Psychiatry. In press